OTCM
ONWRF
Market cap188mUSD
Oct 19, Last price
2.71USD
1Q
-5.57%
IPO
-57.32%
Name
ONWARD Medical NV
Chart & performance
P/E
—
P/S
44.37
EPS
—
Vol. 1Y
—
Shs. 5Y
16.47%
Rev. 5Y
36.42%
Div Yld LY
—
Div Yld TTM
—
Revenues
4m
+4,809.09%
Net income
-42m
L+16.97%
CFO
-39m
L+22.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.
Key people
Rob ten Hoedt
Chairman of the Board · since 2024
Ali Kiboro
Chief Financial Officer · since 2026
John Murphy
Chief Technology Officer · since 2020
Vincent Delattre
Vice President Business Development · since 2016
Hendrik Lambert
Vice President Clinical & Regulatory · since 2016
Dave Marver
Chief Executive Officer, Executive Director · since 2020
Andy Dolan
Vice President Marketing · since 2021
Rano Burkhanova
Global HR Director · since 2020
David Harari
Managing Director USA · since 2019
Rahma Samow
Director · since 2024
Non-Executive Director · since 2025
Roel Bulthuis
Non-Executive Director · since 2020
Gregoire Courtine
Chief Scientific Officer, Non-Executive Director · since 2016
John De Koning
Non-Executive Director · since 2016
Regina Hodits
Non-Executive Director · since 2016
Patrick Van Beneden
Non-Executive Director · since 2016
Curtis Ian
Independent Non-Executive Vice Chairman of the Board · since 2019
Headquarters & legal address
Schimmelt 2
Eindhoven 5611ZX
NL
Eindhoven 5611ZX
NL
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||